NextCell Pharma AB (NXTCL) - Total Liabilities
Based on the latest financial reports, NextCell Pharma AB (NXTCL) has total liabilities worth Skr10.34 Million SEK (≈ $1.11 Million USD) as of August 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NextCell Pharma AB equity growth rate to track the company's year-over-year net asset growth rate.
NextCell Pharma AB - Total Liabilities Trend (2015–2025)
This chart illustrates how NextCell Pharma AB's total liabilities have evolved over time, based on quarterly financial data.
NextCell Pharma AB Competitors by Total Liabilities
The table below lists competitors of NextCell Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S F Capital Bhd
KLSE:8745
|
Malaysia | RM44.86 Million |
|
Draper Esprit PLC
LSE:GROW
|
UK | GBX157.20 Million |
|
Kier Group PLC
LSE:KIE
|
UK | GBX3.04 Billion |
|
Revolver Resources Holdings Ltd
AU:RRR
|
Australia | AU$5.46 Million |
|
ZIGUP plc
LSE:ZIG
|
UK | GBX1.42 Billion |
|
Hindcon Chemicals Limited
NSE:HINDCON
|
India | Rs184.12 Million |
|
Kingsrose Mining Ltd
AU:KRM
|
Australia | AU$5.84 Million |
|
China Yurun Food Group Limited
F:C7Y
|
Germany | €1.24 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down NextCell Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NextCell Pharma AB (NXTCL) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NextCell Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NextCell Pharma AB (2015–2025)
The table below shows the annual total liabilities of NextCell Pharma AB from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | Skr10.34 Million ≈ $1.11 Million |
-24.44% |
| 2024-08-31 | Skr13.69 Million ≈ $1.47 Million |
+4.49% |
| 2023-08-31 | Skr13.10 Million ≈ $1.41 Million |
+43.70% |
| 2022-08-31 | Skr9.12 Million ≈ $981.08K |
+64.75% |
| 2021-08-31 | Skr5.53 Million ≈ $595.49K |
+55.62% |
| 2020-08-31 | Skr3.56 Million ≈ $382.64K |
-5.37% |
| 2019-08-31 | Skr3.76 Million ≈ $404.34K |
+8.31% |
| 2018-08-31 | Skr3.47 Million ≈ $373.31K |
+35.85% |
| 2017-08-31 | Skr2.55 Million ≈ $274.79K |
-5.47% |
| 2016-08-31 | Skr2.70 Million ≈ $290.70K |
+4.40% |
| 2015-08-31 | Skr2.59 Million ≈ $278.46K |
-- |
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more